Stockscreener 앱 받기
7.19
1.27%
0.09
시간 외 거래:
7.19
전일 마감가:
$7.10
열려 있는:
$7.09
하루 거래량:
106.76K
Relative Volume:
0.65
시가총액:
$269.17M
수익:
$128.45M
순이익/손실:
$6.54M
주가수익비율:
143.80
EPS:
0.05
순현금흐름:
$-8.79M
1주 성능:
+6.05%
1개월 성능:
-2.31%
6개월 성능:
+6.36%
1년 성능:
+26.58%
1일 변동 폭
$6.97
$7.24
1주일 범위
$6.61
$7.37
52주 변동 폭
$4.76
$8.85
Lifecore Biomedical Inc Stock (LFCR) Company Profile
명칭
Lifecore Biomedical Inc
전화
(952) 368-4300
주소
3515 LYMAN BOULEVARD, CHASKA
LFCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
7.19 | 266.01M | 128.45M | 6.54M | -8.79M | 0.05 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2025-05-21 | 개시 | William Blair | Outperform |
| 2024-09-05 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
Lifecore Biomedical Inc 주식(LFCR)의 최신 뉴스
Lifecore Biomedical Approves Key Proposals at Annual Meeting - TipRanks
Why pension funds invest in Lifecore Biomedical Inc. (LDE) stock2025 Volume Leaders & Technical Analysis for Trade Confirmation - newser.com
Why millennials buy Lifecore Biomedical Inc. (LDE) stockJuly 2025 Fed Impact & Consistent Profit Trading Strategies - newser.com
Can Lifecore Biomedical Inc. stock beat market expectations this quarterPortfolio Return Report & Weekly High Momentum Picks - newser.com
Is Lifecore Biomedical Inc. (LDE) stock suitable for passive index fundsJuly 2025 Selloffs & Technical Entry and Exit Alerts - newser.com
Will Lifecore Biomedical Inc. (LDE) stock gain from lower interest ratesJuly 2025 Momentum & Daily Profit Focused Screening - newser.com
Is Lifecore Biomedical Inc. (LDE) stock undervalued after correction2025 Support & Resistance & Fast Gain Swing Alerts - newser.com
Is Lifecore Biomedical Inc. forming a reversal patternJuly 2025 Analyst Calls & Real-Time Stock Price Movement Reports - newser.com
What catalysts could drive Lifecore Biomedical Inc. stock higher2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
Can Lifecore Biomedical Inc. stock weather global recessionGlobal Markets & Expert Approved Trade Ideas - newser.com
Is Lifecore Biomedical Inc. stock affected by interest rate hikesIndex Update & Weekly Breakout Stock Alerts - newser.com
Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025 - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect - ACCESS Newswire
Here’s Why Lifecore Biomedical Inc (LFCR) Declined 22% at the End of Q3 - Insider Monkey
Will Lifecore Biomedical Inc. outperform the marketPrice Action & Precise Trade Entry Recommendations - newser.com
Key metrics from Lifecore Biomedical Inc.’s quarterly data2025 Top Gainers & Community Verified Trade Signals - newser.com
Can Lifecore Biomedical Inc. stock surprise with earnings upsidePortfolio Risk Summary & Risk Controlled Daily Trade Plans - newser.com
What hedge fund moves indicate for Lifecore Biomedical Inc. (LDE) stock2025 EndofYear Setup & Fast Momentum Entry Tips - newser.com
Will Lifecore Biomedical Inc. (LDE) stock benefit from infrastructure billGold Moves & Short-Term Swing Trade Alerts - newser.com
Is it too late to sell Lifecore Biomedical Inc.Quarterly Profit Review & Safe Entry Trade Reports - newser.com
Lifecore signs agreement with leading global pharmaceutical company - TipRanks
Lifecore Selected as Commercial Mfg. Partner for Leading Injectable Product - Contract Pharma
Lifecore Biomedical Selects as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company - MarketScreener
What analysts say about Lifecore Biomedical Inc stockTrend Following Strategies & Outstanding Growth Portfolio - earlytimes.in
Lifecore (NASDAQ: LFCR) to transfer manufacturing; second agreement with same multinational - Stock Titan
Lifecore and PolyPeptide link for US peptide manufacturing - Yahoo Finance
Will Lifecore Biomedical Inc. (LDE) stock see insider accumulationJuly 2025 Sector Moves & Free Safe Capital Growth Stock Tips - newser.com
Real time pattern detection on Lifecore Biomedical Inc. stockGap Down & Free High Accuracy Swing Entry Alerts - newser.com
Lifecore, PolyPeptide Partner on Peptide Manufacturing Solution for U.S. Market - Contract Pharma
What sentiment indicators say about Lifecore Biomedical Inc. stockWeekly Investment Report & Smart Investment Allocation Insights - Fundação Cultural do Pará
Lifecore, PolyPeptide collab to offer peptide manufacturing solution - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - ACCESS Newswire
Lifecore, PolyPeptide Partner on Peptide Manufacturing for U.S. Market - Contract Pharma
Lifecore Biomedical, Inc. and Polypeptide Laboratories, Inc. Announce Collaboration Intended to Offer End-To-End Peptide Manufacturing Solution for U.S. Market - MarketScreener
Lifecore and PolyPeptide partner on integrated peptide manufacturing By Investing.com - Investing.com Nigeria
Lifecore and PolyPeptide partner on integrated peptide manufacturing - Investing.com
Will Lifecore Biomedical Inc. (LDE) stock recover faster than industry2025 Trading Recap & Scalable Portfolio Growth Methods - newser.com
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market - The Manila Times
Lifecore Biomedical and PolyPeptide Laboratories Announce Collaboration to Enhance Peptide-Based Pharmaceutical Development - Quiver Quantitative
Lifecore (NASDAQ: LFCR), PolyPeptide sign U.S. DS-to-DP peptide collaboration - Stock Titan
Lifecore Biomedical Inc (LFCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lifecore Biomedical Inc 주식 (LFCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| English Aron R. | 10% Owner |
May 28 '25 |
Sale |
7.12 |
150,419 |
1,071,555 |
264,180 |
| English Aron R. | 10% Owner |
May 23 '25 |
Sale |
6.75 |
96,137 |
649,386 |
1,554,103 |
| English Aron R. | 10% Owner |
May 13 '25 |
Sale |
7.00 |
12,334 |
86,353 |
1,650,240 |
| English Aron R. | 10% Owner |
May 12 '25 |
Sale |
7.03 |
45,698 |
321,426 |
1,662,574 |
| English Aron R. | 10% Owner |
May 08 '25 |
Sale |
7.00 |
5,098 |
35,693 |
1,708,972 |
| English Aron R. | 10% Owner |
May 09 '25 |
Sale |
7.00 |
700 |
4,900 |
1,708,272 |
| English Aron R. | 10% Owner |
May 05 '25 |
Sale |
7.08 |
24,543 |
173,831 |
1,730,618 |
| English Aron R. | 10% Owner |
May 07 '25 |
Sale |
7.01 |
15,847 |
111,099 |
1,714,070 |
| English Aron R. | 10% Owner |
May 06 '25 |
Sale |
7.05 |
701 |
4,940 |
1,729,917 |
| Josephs Paul | Chief Executive Officer |
Jan 08 '25 |
Buy |
5.74 |
17,000 |
97,580 |
559,717 |
3.18%
1.86%
자본화:
|
볼륨(24시간):